Pharmaceuticals, Biotechnology and Life Sciences
Partnership Combines Life Image’s Global Medical Evidence Network Specializing in Imaging Data with Graticule’s Deep Expertise Applying Advanced Data to…
Author John Hawkins has written a well-researched biography about Termeer’s legacy—how he built a global biotech giant, Genzyme, and mentored…
MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured,…
Sygnature Discovery has developed an AR molecular visualisation prototype, meaning that scientists could soon be rotating virtual molecules in the world around them.
The trial is one of the first CAR T cell trials nationwide to enroll prostate cancer patients DUARTE, Calif.–(BUSINESS WIRE)–#CityofHope—City…
The U.S. Food and Drug Administration issued a draft guidance Friday outlining the goals and implementation of a new voluntary conformity assessment initiative, the Accreditation Scheme for Conformity Assessment (ASCA) Pilot, designed to promote consistency and predictability in the premarket review process for medical devices, encourage effective use of FDA resources, and enhance regulatory efficiency, while also enhancing confidence in medical device testing.
The National Institutes of Health awarded six research grants for studies to develop a learning health care system for the treatment of early psychosis, as part of a broad research initiative called Early Psychosis Intervention Network (EPINET), which aims to develop models for the effective delivery of coordinated specialty care (CSC) services for early psychosis.
Counseling and resources available free-of-charge to local community SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Magellan Health, Inc. (NASDAQ: MGLN) today announced that it will…
Despite technological advancements, the pressing matter pharma companies have to address is how to achieve more control over their operations within and outside the facilities to remain competitive, optimize time-to-market, avoid shipment delays, and reduce the waste.
New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), experienced more heart attacks, strokes and other cardiovascular events when they were unable to obtain their prescribed PCSK9 inhibitor (PCSK9i), a cholesterol-lowering treatment.